MCM
MRVI icon

Moore Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Moore Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-28,257
Closed -$793K – 744
2020
Q4 		$793K Buy
+28,257
New +$787K 0.01% 430

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Moore Capital Management's MRVI Position: Q1 2021 in Review

Moore Capital Management sold out of Maravai LifeSciences (MRVI) in Q1 2021, closing a stake of 28,257 shares — an estimated $793K sold.

Moore Capital Management first reported a position in MRVI in Q4 2020 and held it in 1 quarter. The position peaked at $793K in Q4 2020. 144 funds tracked by Wall St. Rank hold MRVI as of Q1 2021.

  • Moore Capital Management reported no remaining Maravai LifeSciences position as of Q1 2021 after selling out during the quarter.
  • Moore Capital Management sold 28,257 Maravai LifeSciences shares in Q1 2021, an estimated $793K.
  • Moore Capital Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 1 quarter.
  • Moore Capital Management's Maravai LifeSciences position peaked at $793K in Q4 2020.
  • 144 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2021.

Based on Moore Capital Management's 13F filing for Q1 2021, filed 17 May 2021.